Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVA5NS)

• Drug Name: BAY-57-9352 Drug Info
• Synonyms: Telatinib; Bay 57-9352

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 9808844
  CAS Number: CAS 332012-40-5
  TTD Drug ID: DMVA5NS

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[4]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[5]
Fruquintinib	DMHOSCQ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[6]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[5]
Vorolanib	DMIM1U9	Non-small cell lung cancer	2C25	Phase 2	[8]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[9]
ASP-8477	DMBZQS7	Neuropathic pain	8E43.0	Phase 2	[10]
AG-013958	DMRET3H	Age-related macular degeneration	9B75.0	Phase 1/2	[11]

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[12]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[4]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[13]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[14]
Rosiglitazone + metformin	DMPIDXT	Diabetic complication	5A2Y	Phase 3	[3]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[3]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[15]
Vorolanib	DMIM1U9	Non-small cell lung cancer	2C25	Phase 2	[8]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[16]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[17]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[18]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[19]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[20]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[21]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[12]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[22]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[23]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[3]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Inhibitor	[1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021605)
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [7] National Cancer Institute Drug Dictionary (drug id 452042).
• [8] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [9] CA patent application no. 841416, Method of selecting therapeutic indications.
• [10] ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
• [11] Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [13] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [14] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [15] National Cancer Institute Drug Dictionary (drug id 695817).
• [16] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
• [17] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [18] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [20] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [21] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [22] Clinical pipeline report, company report or official report of Exelixis (2011).
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [24] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.